Mesoblast (Mesoblast) Price-to-Tangible-Book

: (As of Today)

View and export this data going back to 2006. Start your Free Trial

As of today (2024-04-24), Mesoblast's share price is $0.6051. Mesoblast's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $-0.07. Hence, Mesoblast's Price to Tangible Book Ratio of today is .

The historical rank and industry rank for Mesoblast's Price-to-Tangible-Book or its related term are showing as below:

During the past 13 years, Mesoblast's highest Price to Tangible Book Ratio was 938.67. The lowest was 54.14. And the median was 496.41.

MEOBF's Price-to-Tangible-Book is not ranked ^*
in the Biotechnology industry.
Industry Median: 2.69
* Ranked among companies with meaningful Price-to-Tangible-Book only.

A closely related ratio is called PB Ratio. As of today, Mesoblast's share price is $0.6051. Mesoblast's Book Value per Sharefor the quarter that ended in Dec. 2023 was $0.50. Hence, Mesoblast's P/B Ratio of today is 1.21.

Mesoblast Price-to-Tangible-Book Historical Data

The historical data trend for Mesoblast's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mesoblast Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Price-to-Tangible-Book

Get a 7-Day Free Trial

1,520.00

Mesoblast Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Price-to-Tangible-Book	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison

For the Biotechnology subindustry, Mesoblast's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mesoblast Price-to-Tangible-Book Distribution

For the Biotechnology industry and Healthcare sector, Mesoblast's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Mesoblast's Price-to-Tangible-Book falls into.

Mesoblast Price-to-Tangible-Book Calculation

Mesoblast's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Dec. 2023 )
	=	0.6051	/	-0.067
	=

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

Mesoblast Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Mesoblast's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

Mesoblast (Mesoblast) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mesoblast Ltd (OTCPK:MEOBF) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

MESO:USA LWB:Germany MSB:Australia

Address

Level 38, 55 Collins Street, Melbourne, VIC, AUS, 3000

Website

https://www.mesoblast.com

Mesoblast Ltd is a clinical-stage biotechnology company. It develops and commercializes innovative allogeneic cellular medicines to treat complex diseases resistant to the conventional standard of care. Its portfolio of Phase 3 product candidates comprises remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD), and for moderate to severe acute respiratory distress syndrome (ARDS) and others.